{"podcast":{"title":"Core IM | Internal Medicine Podcast","slug":"core-im-internal-medicine-podcast-60389","podcast_index_feed_id":60389,"rss_url":"https://feeds.redcircle.com/2c03e755-c428-4b8e-9150-95ef1ed2492b","website_url":"https://redcircle.com/shows/core-im-internal-medicine-podcast","image_url":"https://media.redcircle.com/images/2025/6/13/2/b2137ab0-0bbb-43a6-aaaa-b4b07adec3de_fcdc-ce25-48d2-986c-b209f60d7ebb_496745-915727.jpg","author":"Core IM Team","episode_count":217,"summary":"Core Internal Medicine via following series: 5 Pearls || Clinically relevant pearls Mind the Gap || Why do we do what we do? Gray Matters || Management Reasoning Hoofbeats || Dissecting clinical reasoning At the Bedside || Explore everyday challenges","last_synced_at":"2026-06-10T20:19:29.041629+00:00","page_url":"https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389"},"episode":{"title":"#197 Hypercoagulability Part 2: 5 Pearls Segment","slug":"197-hypercoagulability-part-2-5-pearls-segment","published_at":"2026-01-07T09:04:54+00:00","page_url":"https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/197-hypercoagulability-part-2-5-pearls-segment","show_page_url":"https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389","url":"https://www.coreimpodcast.com/2026/01/07/hypercoagulability-part-2/","audio_url":"https://pscrb.fm/rss/p/audio2.redcircle.com/episodes/fff5139d-429f-4d96-b466-058b6cfad2bc/stream.mp3","summary":"Gray zones of VTE management! How to approach anticoagulation duration in unprovoked, provoked-irreversible, and provoked-reversible clots? When dose-reduced DOACs make sense for long-term secondary prevention? What truly constitutes DOAC failure? We also devle into how APLAS a critical do-not-miss diagnosis that changes management entirely. 🔹 Sponsor : Pain Management and Opioids Adaptive Learning Free Online Course by NEJM Group: https://cme-info.nejm.org/core-im/ 🔹 Transcript & Shownotes (2:56) - (13:15) | PEARL 1: Managing clots in the “unprovoked”/provoked-irreversible patient (13:21) - (18:10) | PEARL 2: Managing provoked, “reversible” clots (18:14) - (25:14) | PEARL 3: DOAC failure: time to step it up? (25:20) - (37:25) | PEARL 4: APLAS: the exception to everything Tags: CoreIM, Internal Medicine, ClinicalPearls, Medical Education, IMCore, hospitalist, physician assistant, nurse practitioner, medical student, internal medicine, hematology Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy","meta_description":"Gray zones of VTE management! How to approach anticoagulation duration in unprovoked, provoked-irreversible, and provoked-reversible clots? When dose-redu…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2306,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/core-im-internal-medicine-podcast-60389/episodes/197-hypercoagulability-part-2-5-pearls-segment/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/core-im-internal-medicine-podcast-60389/197-hypercoagulability-part-2-5-pearls-segment.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}